Milestone Pharmaceuticals’ (MIST) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report sent to investors on Monday morning, Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Separately, Rodman & Renshaw started coverage on Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective on the stock.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.47 on Monday. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $3.52. The firm’s 50-day simple moving average is $1.47 and its two-hundred day simple moving average is $1.53. The stock has a market cap of $78.29 million, a PE ratio of -1.18 and a beta of 1.72. The company has a debt-to-equity ratio of 1.61, a quick ratio of 19.13 and a current ratio of 19.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. Analysts anticipate that Milestone Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its position in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after buying an additional 10,800 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the period. Finally, Lion Point Capital LP grew its holdings in Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after purchasing an additional 40,000 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.